{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:57:10Z","timestamp":1792324630449,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.chest.2023.08.009","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T06:37:50Z","timestamp":1691735870000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Low-Dose vs\u00a0Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in\u00a0Patients Not Infected With HIV"],"prefix":"10.1016","volume":"165","author":[{"given":"Tatsuya","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9093-3442","authenticated-orcid":false,"given":"Ayumu","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shinichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watari","family":"Tomohisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6080-1801","authenticated-orcid":false,"given":"Kei","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.chest.2023.08.009_bib1","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2023.08.009_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10156-012-0453-0","article-title":"Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies","volume":"18","author":"Tasaka","year":"2012","journal-title":"J\u00a0Infect Chemother"},{"issue":"10","key":"10.1016\/j.chest.2023.08.009_bib3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3201\/eid1010.030985","article-title":"Current epidemiology of Pneumocystis pneumonia","volume":"10","author":"Morris","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.chest.2023.08.009_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3201\/eid1903.121151","article-title":"Increasing Pneumocystis pneumonia, England, UK, 2000-2010","volume":"19","author":"Maini","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.chest.2023.08.009_bib5","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.chest.2023.08.009_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An Official American Thoracic Society Statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2023.08.009_bib8","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/14656566.2021.1915989","article-title":"Pneumocystis jirovecii: a review with a focus on prevention and treatment","volume":"22","author":"Weyant","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.chest.2023.08.009_bib9","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/jac\/dks283","article-title":"Acute psychosis related to use of trimethoprim\/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study","volume":"67","author":"Lee","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.chest.2023.08.009_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jcma.2016.01.007","article-title":"High daily doses of trimethoprim\/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS","volume":"79","author":"Chang","year":"2016","journal-title":"J\u00a0Chin Med Assoc"},{"issue":"6","key":"10.1016\/j.chest.2023.08.009_bib11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","article-title":"Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study","volume":"51","author":"Nakashima","year":"2018","journal-title":"J\u00a0Microbiol Immunol Infect"},{"issue":"12","key":"10.1016\/j.chest.2023.08.009_bib12","doi-asserted-by":"crossref","first-page":"ofab545","DOI":"10.1093\/ofid\/ofab545","article-title":"On the treatment of Pneumocystis jirovecii pneumonia: current practice based on outdated evidence","volume":"8","author":"McDonald","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.chest.2023.08.009_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jiac.2018.11.014","article-title":"Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: a retrospective multicenter study","volume":"25","author":"Ohmura","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"issue":"12","key":"10.1016\/j.chest.2023.08.009_bib14","doi-asserted-by":"crossref","first-page":"e01173","DOI":"10.1128\/AAC.01173-17","article-title":"A\u00a0four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia in patients without HIV infection","volume":"61","author":"Kosaka","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.chest.2023.08.009_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s15010-015-0851-1","article-title":"Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study","volume":"44","author":"Creemers-Schild","year":"2016","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.chest.2023.08.009_bib16","doi-asserted-by":"crossref","first-page":"ofaa112","DOI":"10.1093\/ofid\/ofaa112","article-title":"Low-dose TMP-SMX in the treatment of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"7","author":"Butler-Laporte","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.chest.2023.08.009_bib17","doi-asserted-by":"crossref","first-page":"e1252","DOI":"10.1093\/cid\/ciac386","article-title":"Treatment with reduced dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies","volume":"76","author":"Hammarstrom","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.chest.2023.08.009_bib18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1056\/NEJMc070728","article-title":"Pneumocystis pneumonia associated with infliximab in Japan","volume":"357","author":"Harigai","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.chest.2023.08.009_bib19","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","article-title":"Pneumocystis jirovecii disease: basis for the revised EORTC\/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus","volume":"72","author":"Lagrou","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.chest.2023.08.009_bib20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cmi.2020.05.024","article-title":"Diagnostic accuracy of serum (1-3)-beta-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"26","author":"Del Corpo","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.chest.2023.08.009_bib21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1186\/s12879-021-06895-x","article-title":"Low cut-off value of serum (1,3)-beta-D-glucan for the diagnosis of Pneumocystis pneumonia in non-HIV patients: a retrospective cohort study","volume":"21","author":"Taniguchi","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"16","key":"10.1016\/j.chest.2023.08.009_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"11","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"25","key":"10.1016\/j.chest.2023.08.009_bib24","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"23","key":"10.1016\/j.chest.2023.08.009_bib25","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.chest.2023.08.009_bib26","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.cmi.2020.02.021","article-title":"Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study","volume":"26","author":"Rajput","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"35","key":"10.1016\/j.chest.2023.08.009_bib27","doi-asserted-by":"crossref","first-page":"59729","DOI":"10.18632\/oncotarget.19927","article-title":"Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.chest.2023.08.009_bib28","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/jac\/dkw155","article-title":"Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Cordonnier","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.chest.2023.08.009_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/AAC.5.3.289","article-title":"Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis","volume":"5","author":"Hughes","year":"1974","journal-title":"Antimicrob Agents Chemother"},{"issue":"13 Spec No","key":"10.1016\/j.chest.2023.08.009_bib30","first-page":"47","article-title":"Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole","volume":"112","author":"Hughes","year":"1975","journal-title":"Can Med Assoc J"},{"issue":"6","key":"10.1016\/j.chest.2023.08.009_bib31","doi-asserted-by":"crossref","first-page":"762","DOI":"10.7326\/0003-4819-92-6-762","article-title":"Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia","volume":"92","author":"Winston","year":"1980","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.chest.2023.08.009_bib32","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","article-title":"Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target","volume":"56","author":"Martinez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.chest.2023.08.009_bib33","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","article-title":"Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients","volume":"17","author":"Rodriguez","year":"2004","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"10.1016\/j.chest.2023.08.009_bib34","first-page":"CD005590","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.chest.2023.08.009_bib35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2023.08.009_bib36","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3390\/ijerph19052833","article-title":"Trimethoprim-sulfamethoxazole (Bactrim) dose optimization in Pneumocystis jirovecii pneumonia (PCP) management: a systematic review","volume":"19","author":"Haseeb","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"10.1016\/j.chest.2023.08.009_bib37","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM199009203231202","article-title":"Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone","volume":"323","author":"Medina","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.chest.2023.08.009_bib38","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2023.08.009_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2110-5820-4-13","article-title":"Cotrimoxazole - optimal dosing in the critically ill","volume":"4","author":"Brown","year":"2014","journal-title":"Ann Intensive Care"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223052698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223052698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T01:07:39Z","timestamp":1715130459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223052698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0012369223052698"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.08.009","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose vs\u00a0Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in\u00a0Patients Not Infected With HIV","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}